Literature DB >> 8387568

Detection of CMV-matrix pp65 antigen in leucocytes by immunofluorescence as a marker of CMV disease.

A Ehrnst1, L Barkholt, C Brattström, J Czajkowski, O Teodosiu, J Tollemar, P Ljungman.   

Abstract

The finding that active cytomegalovirus (CMV) infection is associated with an increased mortality after organ transplantation and the introduction of successful antiviral treatment render more urgent the development of rapid and accurate diagnostic methods. Rapid immunodiagnosis of active CMV infection was investigated by means of immunofluorescence staining of leucocytes by monoclonal antibodies. Monoclonals directed against the matrix protein, pp65, and ClonabR monoclonal antibody, which has been claimed to be directed against immediate early antigens, were used. All monoclonal antibodies directed against the matrix protein reacted equally well in staining of polymorphonuclear cells. Monoclonals described by Gerna et al. [1991] and by Pereira et al. [1982] also reacted more clearly with mononuclear cells. One hundred fifty heparinized blood samples were collected monthly from 82 patients within 3 months after transplantation. In addition, 132 EDTA blood samples were tested in connection with suspected CMV infection. The latter approach gave a better agreement between antigen detection and virus isolation. There was a relationship between active CMV infection and the finding of antigen-positive leucocytes (P = 0.002, Fisher's exact test) found within 1 month of one another. When the number of antigen-positive cells was taken into account, a relationship to severe CMV disease was detected (P < 0.001, Fisher's exact test). The antigen test was positive at an early stage during the development of severe CMV disease. This rapid method is useful for following the disease process of CMV and in determining when to initiate antiviral treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387568     DOI: 10.1002/jmv.1890390207

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

1.  A three-center European external quality control study of PCR for detection of cytomegalovirus DNA in blood.

Authors:  J E Grundy; A Ehrnst; H Einsele; V C Emery; H Hebart; H G Prentice; P Ljungman
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

2.  Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.

Authors:  Guenther Koehne; Aisha Hasan; Ekaterina Doubrovina; Susan Prockop; Eleanor Tyler; Gloria Wasilewski; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-29       Impact factor: 5.742

3.  Use of laboratory assays to predict cytomegalovirus disease in renal transplant recipients.

Authors:  C Y Tong; L Cuevas; H Williams; A Bakran
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

4.  Role of antigenemia assay in the early diagnosis and prediction of human cytomegalovirus organ involvement in AIDS patients.

Authors:  D Francisci; A Tosti; R Preziosi; F Baldelli; G Stagni; S Pauluzzi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-06       Impact factor: 3.267

5.  Fulminant anaplastic large cell lymphoma (ALCL) concomitant with primary cytomegalovirus (CMV) infection, and human herpes virus 8 (HHV-8) infection together with Epstein-Barr-virus (EBV) reactivation in a patient with asymptomatic HIV-infection.

Authors:  Sven Grützmeier; Anna Porwit; Corinna Schmitt; Eric Sandström; Börje Åkerlund; Ingemar Ernberg
Journal:  Infect Agent Cancer       Date:  2016-08-22       Impact factor: 2.965

6.  Cytomegalovirus pneumonia in a patient with T-lymphoblastic leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: A case report.

Authors:  Qiuyu Li; Kai Wang; Wei Guo; Ming Lu
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.